Capital BioVentures Launches ASCENT26: Accelerating Canada’s Next Therapeutic Breakthroughs

Capital BioVentures (CBV), a Canadian biotech accelerator supporting the growth of early-stage life sciences companies, recently announced the launch of ASCENT26, the second cohort of its ASCENT program. Nine Canadian therapeutics companies have been selected to participate in the six-month virtual program, which provides targeted support to navigate critical development, corporate, and financing milestones.

Congratulations to the nine selected companies! We are proud to share that five of the selected companies, BLOCK Biosciences, CereCura Nanotherapeutics, LongTermGevity, Stoked Bio, and Telescope Therapeutics are OBIO-affiliated companies.

CBV is an OBIO® member and partner.